ATE499088T1 - Glp-1-fc fusionsprotein-formulierung - Google Patents

Glp-1-fc fusionsprotein-formulierung

Info

Publication number: ATE499088T1
Authority: AT; Austria
Prior art keywords: glp; fusion protein; protein formulation; formulation; polysorbate
Prior art date: 2007-07-10

Application number

AT08772467T

Other languages

English (en)

Inventor

Kingman Ng

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-10

Filing date

2008-07-09

Publication date

2011-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39870243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE499088(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-09 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE499088T1 publication Critical patent/ATE499088T1/de

Links

238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
108020001507 fusion proteins Proteins 0.000 title abstract 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
239000007979 citrate buffer Substances 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000037865 fusion proteins Human genes 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
229940068968 polysorbate 80 Drugs 0.000 abstract 1
229920000053 polysorbate 80 Polymers 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT08772467T 2007-07-10 2008-07-09 Glp-1-fc fusionsprotein-formulierung ATE499088T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94885507P	2007-07-10	2007-07-10
PCT/US2008/069473 WO2009009562A2 (en)	2007-07-10	2008-07-09	Glp-1-fc fusion protein formulation

Publications (1)

Publication Number	Publication Date
ATE499088T1 true ATE499088T1 (de)	2011-03-15

Family

ID=39870243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08772467T ATE499088T1 (de)	2007-07-10	2008-07-09	Glp-1-fc fusionsprotein-formulierung

Country Status (18)

Country	Link
US (1)	US20100196405A1 (de)
EP (1)	EP2175834B8 (de)
JP (1)	JP2010533197A (de)
KR (1)	KR20100020516A (de)
CN (1)	CN101730523A (de)
AT (1)	ATE499088T1 (de)
AU (1)	AU2008275180A1 (de)
BR (1)	BRPI0813699B1 (de)
CA (1)	CA2691695C (de)
DE (1)	DE602008005155D1 (de)
EA (1)	EA201070121A1 (de)
HR (1)	HRP20110242T1 (de)
MX (1)	MX2010000380A (de)
NZ (1)	NZ582480A (de)
RS (1)	RS52378B (de)
UA (1)	UA97673C2 (de)
WO (1)	WO2009009562A2 (de)
ZA (1)	ZA201000149B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011090305A2 (en) *	2010-01-19	2011-07-28	Hanmi Holdings Co., Ltd	Liquid formulations for long-acting g-csf conjugate
JP5800527B2 (ja) *	2010-03-30	2015-10-28	日東電工株式会社	安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
CN102533655A (zh) *	2010-12-21	2012-07-04	青岛黄海制药有限责任公司	高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
UA114710C2 (uk)	2011-06-10	2017-07-25	Ханмі Сайенс Ко., Лтд.	Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить
JP6038905B2 (ja)	2011-06-17	2016-12-07	ハンミサイエンスカンパニーリミテッド	オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
CN105636976A (zh) *	2012-07-20	2016-06-01	庆熙大学校产学协力团	新型肽标签以及其用途
AR091902A1 (es) *	2012-07-25	2015-03-11	Hanmi Pharm Ind Co Ltd	Formulacion liquida de un conjugado de insulina de accion prolongada
US10441665B2 (en)	2012-07-25	2019-10-15	Hanmi Pharm. Co., Ltd.	Liquid formulation of long acting insulinotropic peptide conjugate
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092862A1 (es) *	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) *	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6363612B2 (ja)	2012-11-06	2018-07-25	ハンミファーマシューティカルカンパニーリミテッド	オキシントモジュリンと免疫グロブリンのフラグメントとを含むタンパク質結合体の液状製剤
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
LT2934568T (lt)	2012-12-21	2018-02-12	Sanofi	Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
CN104173275A (zh) *	2013-05-21	2014-12-03	深圳翰宇药业股份有限公司	度拉鲁肽注射剂及其制备方法
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN104293834B (zh) *	2014-10-11	2018-03-23	上海兴迪金生物技术有限公司	GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
EP3257524B1 (de) *	2015-02-11	2020-08-26	Gmax Biopharm LLC	Stabilisiertes lösungspräparat eines pharmazeutischen glp-1r-antikörperfusionsproteins
AR105616A1 (es)	2015-05-07	2017-10-25	Lilly Co Eli	Proteínas de fusión
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN107661288A (zh) *	2016-07-29	2018-02-06	江苏泰康生物医药有限公司	含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备
CN107698684B (zh) *	2016-08-03	2021-09-28	广东东阳光药业有限公司	包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白
CN108210890A (zh) *	2016-12-09	2018-06-29	江苏泰康生物医药有限公司	重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂
GB201621987D0 (en) *	2016-12-22	2017-02-08	Archer Virgil L See Archer Sheri A Arecor Ltd	Novel composition
SI3630164T1 (sl)	2017-06-01	2023-10-30	Eli Lilly And Company	Dulaglutid za zdravljenje kronične ledvične bolezni
MX2020001707A (es)	2017-08-15	2020-03-20	Kindred Biosciences Inc	Variantes igg fc para uso veterinario.
MA50798A (fr) *	2017-11-21	2020-09-30	Lilly Co Eli	Procédés d'utilisation et compositions contenant du dulaglutide
CN116143939A (zh) *	2017-11-24	2023-05-23	浙江道尔生物科技有限公司	一种治疗代谢疾病的多重活性蛋白
TWI705820B (zh)	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
CN113613629A (zh)	2019-03-15	2021-11-05	伊莱利利公司	防腐的制剂
CA3056663C (en)	2019-04-05	2022-10-18	Jeffrey S. RIESMEYER	Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
GB201917723D0 (en) *	2019-12-04	2020-01-15	Nv Rose Llc	Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
KR102349717B1 (ko) *	2020-03-12	2022-01-11	주식회사 에스엘메타젠	신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
CN114053217B (zh) *	2020-08-03	2023-04-18	华兰生物工程股份有限公司	一种Exendin-4-Fc融合蛋白注射制剂及其制备方法
CN112494658B (zh) *	2020-12-04	2024-07-12	苏州药明生物技术有限公司	一种稳定的Fc融合蛋白制剂
CN114685644A (zh)	2020-12-29	2022-07-01	苏州康宁杰瑞生物科技有限公司	一种人glp-1多肽变体及其应用
AU2022308120A1 (en)	2021-07-06	2024-02-08	Suzhou Alphamab Co., Ltd.	Fusion protein and application thereof
KR20250162621A (ko)	2023-03-23	2025-11-18	일라이 릴리 앤드 캄파니	Fc-함유 단백질을 생산하는 방법
CN117143242B (zh) *	2023-10-30	2024-03-29	南京佰抗生物科技有限公司	抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025122835A2 (en)	2023-12-08	2025-06-12	Eli Lilly And Company	Methods of producing fc-containing proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007007565A (es) *	2004-12-22	2007-07-24	Lilly Co Eli	Formulaciones de proteina de fusion analoga del peptido-1similar al glucagon (glp-1).

2008
- 2008-07-09 RS RS20110188A patent/RS52378B/sr unknown
- 2008-07-09 CA CA2691695A patent/CA2691695C/en active Active
- 2008-07-09 EP EP08772467A patent/EP2175834B8/de active Active
- 2008-07-09 MX MX2010000380A patent/MX2010000380A/es active IP Right Grant
- 2008-07-09 NZ NZ582480A patent/NZ582480A/en unknown
- 2008-07-09 BR BRPI0813699-8A patent/BRPI0813699B1/pt active IP Right Grant
- 2008-07-09 DE DE602008005155T patent/DE602008005155D1/de active Active
- 2008-07-09 KR KR1020107000435A patent/KR20100020516A/ko not_active Ceased
- 2008-07-09 CN CN200880023539A patent/CN101730523A/zh active Pending
- 2008-07-09 EA EA201070121A patent/EA201070121A1/ru unknown
- 2008-07-09 US US12/665,053 patent/US20100196405A1/en not_active Abandoned
- 2008-07-09 HR HR20110242T patent/HRP20110242T1/hr unknown
- 2008-07-09 WO PCT/US2008/069473 patent/WO2009009562A2/en not_active Ceased
- 2008-07-09 AT AT08772467T patent/ATE499088T1/de not_active IP Right Cessation
- 2008-07-09 UA UAA201000210A patent/UA97673C2/ru unknown
- 2008-07-09 JP JP2010516211A patent/JP2010533197A/ja not_active Withdrawn
- 2008-07-09 AU AU2008275180A patent/AU2008275180A1/en not_active Abandoned
2010
- 2010-01-08 ZA ZA2010/00149A patent/ZA201000149B/en unknown

Also Published As

Publication number	Publication date
WO2009009562A3 (en)	2009-07-09
CN101730523A (zh)	2010-06-09
HK1141237A1 (en)	2010-11-05
CA2691695C (en)	2014-03-18
ZA201000149B (en)	2011-04-28
BRPI0813699B1 (pt)	2021-06-22
UA97673C2 (ru)	2012-03-12
EA201070121A1 (ru)	2010-06-30
WO2009009562A2 (en)	2009-01-15
AU2008275180A1 (en)	2009-01-15
BRPI0813699A2 (pt)	2014-12-30
CA2691695A1 (en)	2009-01-15
JP2010533197A (ja)	2010-10-21
MX2010000380A (es)	2010-03-29
KR20100020516A (ko)	2010-02-22
DE602008005155D1 (de)	2011-04-07
US20100196405A1 (en)	2010-08-05
EP2175834B8 (de)	2012-08-22
RS52378B (sr)	2012-12-31
EP2175834A2 (de)	2010-04-21
HRP20110242T1 (hr)	2011-05-31
NZ582480A (en)	2011-03-31
EP2175834B1 (de)	2011-02-23

Legal Events

Date	Code	Title	Description
2011-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE499088T1 (de)	2011-03-15	Glp-1-fc fusionsprotein-formulierung
MY147643A (en)	2012-12-31	Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
BR0313629B1 (pt)	2013-04-02	composiÇço detergente bifÁsica lÍquida aquosa de limpeza pessoal.
ATE396731T1 (de)	2008-06-15	Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
EA200601776A1 (ru)	2007-04-27	Метадоновые композиции местного действия и способы их применения
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
EA200900662A1 (ru)	2009-12-30	Лечение синдрома "сухого глаза" с помощью тестостерона и прогестагена
ATE506951T1 (de)	2011-05-15	Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
BRPI0512944A (pt)	2008-04-15	agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1
CL2007003690A1 (es)	2008-08-22	Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
ZA200501128B (en)	2006-10-25	Biphasic composition induced by polydextrose
BRPI0722054A2 (pt)	2014-04-01	Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
DE602005019416D1 (de)	2010-04-01	Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
ATE464045T1 (de)	2010-04-15	Zusammensetzung aus milchsäure und lactoferrin
ITTO20050715A1 (it)	2007-04-08	Calzatura per la prevenzione e la correzione dell'alluce valgo
WO2007095609A3 (en)	2007-10-11	Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
EA200800537A1 (ru)	2008-06-30	Маррубиин и композиция для уменьшения храпа, упаковка и методика
ATE458482T1 (de)	2010-03-15	Verwendung von amino substituierten benzimidazolen
DE112006002041A5 (de)	2008-04-30	Pharmazeutisch wirksame Zusammensetzung zur Behandlung von Diabetes
WO2007067611A3 (en)	2008-03-06	Methods of treating cardiac reperfusion disease
UA95094C2 (ru)	2011-07-11	Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
ITRM20050296A1 (it)	2006-12-09	Composizione ad elevata stabilita' per il trattamento anticorrosivo e antincrostante di acqua sanitaria.